Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for dementia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on dementia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on dementia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Medical Cannabis for the Treatment of Dementia: A Review of Clinical Effectiveness and Guidelines Last updated: July 17, 2019 Project Number: RC1152-000 Product (...) Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of medical cannabis for the treatment of dementia? What are the evidence-based guidelines associated with the use of medical cannabis for the treatment of dementia? Key Message Limited evidence from one systematic review3 and one uncontrolled before-and-after study10 suggested that medical cannabis may be effective for treating agitation, disinhibition, irritability
Dementia Revised 2019 ACR Appropriateness Criteria ® 1 Dementia American College of Radiology ACR Appropriateness Criteria ® Dementia Variant 1: Cognitive decline. Suspected Alzheimer disease. Initial imaging. Procedure Appropriateness Category Relative Radiation Level MRI head without IV contrast Usually Appropriate O CT head without IV contrast Usually Appropriate ??? F-18 amyloid PET/CT brain May Be Appropriate ??? FDG-PET/CT brain May Be Appropriate ???? MRI head without and with IV (...) contrast Usually Not Appropriate O Tc-99m HMPAO SPECT/CT brain Usually Not Appropriate ???? MR spectroscopy head without IV contrast Usually Not Appropriate O MRI functional (fMRI) head without IV contrast Usually Not Appropriate O CT head with IV contrast Usually Not Appropriate ??? CT head without and with IV contrast Usually Not Appropriate ??? Variant 2: Suspected frontotemporal dementia. Initial imaging. Procedure Appropriateness Category Relative Radiation Level MRI head without IV contrast
Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down (...) Individual Login Purchase options menu search Advertisement close Deprescribing cholinesterase inhibitors and memantine in dementia: guideline summary Emily Reeve, Barbara Farrell, Wade Thompson, Nathan Herrmann, Ingrid Sketris, Parker J Magin, Lynn Chenoweth, Mary Gorman, Lyntara Quirke, Graeme Bethune and Sarah N Hilmer Med J Aust 2019; 210 (4): . || doi: 10.5694/mja2.50015 Published online: 4 March 2019 Topics Abstract Introduction: Cholinesterase inhibitors (ChEIs) and memantine are medications used
Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools (...) to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources
Dementia. Alzheimer disease (AD) and other dementia syndromes are becoming more common; an estimated 5.5 million adults aged 65 years or older are living with AD in the United States. It is important for primary care physicians to gain knowledge in this field because most community-dwelling older adults receive their care from them. This article discusses the latest findings in approaches to prevent cognitive decline as well as dementia screening, diagnosis, and treatment. Approaches to address (...) quality of life for persons with dementia and their caregivers are also discussed.
Steps to better understanding resistant behaviours in hospitalised patients with dementia. The studyFeatherstone K, Northcott A, Harden J, et al. Refusal and resistance to care by people living with dementia being cared for within acute hospital wards: an ethnographic study. Health Serv Deliv Res 2019;7.This study was funded by the National Institute for Health Research Health Services and Delivery Research Programme (project number 13/10/80).To read the full NIHR Signal, go to https (...) ://discover.dc.nihr.ac.uk/content/signal-000779/understanding-dementia-care-in-hospitals.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Association of Midlife to Late-Life Blood Pressure Patterns With Incident Dementia. The association between late-life blood pressure (BP) and cognition may depend on the presence and chronicity of past hypertension. Late-life declines in blood pressure following prolonged hypertension may be associated with poor cognitive outcomes.To examine the association of midlife to late-life BP patterns with subsequent dementia, mild cognitive impairment, and cognitive decline.The Atherosclerosis Risk (...) on December 31, 2017.Five groups based on longitudinal patterns of normotension, hypertension (>140/90 mm Hg), and hypotension (<90/60 mm Hg) at visits 1 to 5.Primary outcome was dementia onset after visit 5, based on Ascertain Dementia-8 informant questionnaires, Six-Item Screener telephone assessments, hospital discharge and death certificate codes, and the visit 6 neurocognitive evaluation. Secondary outcome was mild cognitive impairment at visit 6, based on the neurocognitive evaluation.Among 4761
Association of ideal cardiovascular health at age 50 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. To examine the association between the Life Simple 7 cardiovascular health score at age 50 and incidence of dementia.Prospective cohort study.Civil service departments in London (Whitehall II study; study inception 1985-88).7899 participants with data on the cardiovascular health score at age 50.The cardiovascular health score included four behavioural (smoking, diet (...) , physical activity, body mass index) and three biological (fasting glucose, blood cholesterol, blood pressure) metrics, coded on a three point scale (0, 1, 2). The cardiovascular health score was the sum of seven metrics (score range 0-14) and was categorised into poor (scores 0-6), intermediate (7-11), and optimal (12-14) cardiovascular health.Incident dementia, identified through linkage to hospital, mental health services, and mortality registers until 2017.347 incident cases of dementia were
Association of Lifestyle and Genetic Risk With Incidence of Dementia. Genetic factors increase risk of dementia, but the extent to which this can be offset by lifestyle factors is unknown.To investigate whether a healthy lifestyle is associated with lower risk of dementia regardless of genetic risk.A retrospective cohort study that included adults of European ancestry aged at least 60 years without cognitive impairment or dementia at baseline. Participants joined the UK Biobank study from 2006 (...) to 2010 and were followed up until 2016 or 2017.A polygenic risk score for dementia with low (lowest quintile), intermediate (quintiles 2 to 4), and high (highest quintile) risk categories and a weighted healthy lifestyle score, including no current smoking, regular physical activity, healthy diet, and moderate alcohol consumption, categorized into favorable, intermediate, and unfavorable lifestyles.Incident all-cause dementia, ascertained through hospital inpatient and death records.A total
Setting goals can help people with early stage dementia improve function. The studyClare L, Kudlicka A, Oyebode J R, et al. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT. Health Technol Assess 2019;23:1-242.The trial was funded by the NIHR Health Technology Assessment Programme (project number11/15/04).To read the full NIHR Signal, go to: https://discover.dc.nihr.ac.uk/content/signal-000767/goal-setting-in-early-stage-dementia-can
Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. A National Institute on Aging and Alzheimer's Association workgroup proposed a research framework for Alzheimer disease in which biomarker classification of research participants is labeled AT(N) for amyloid, tau, and neurodegeneration biomarkers.To determine the associations between AT(N) biomarker profiles and memory decline in a population-based cohort (...) of individuals without dementia age 60 years or older, and to determine whether biomarkers provide incremental prognostic value beyond more readily available clinical and genetic information.Population-based cohort study of cognitive aging in Olmsted County, Minnesota, that included 480 nondemented Mayo Clinic Study of Aging participants who had a clinical evaluation and amyloid positron emission tomography (PET) (A), tau PET (T), and magnetic resonance imaging (MRI) cortical thickness (N) measures between
ACR–ASNR Practice Parameter for Brain PET/CT Imaging Dementia Res. 17 – 2015 - 2019 PRACTICE PARAMETER Brain Dementia PET/CT Imaging / 1 The American College of Radiology, with more than 30,000 members, is the principal organization of radiologists, radiation oncologists, and clinical medical physicists in the United States. The College is a nonprofit professional society whose primary purposes are to advance the science of radiology, improve radiologic services to the patient, study (...) in each document. Reproduction or modification of the published practice parameter and technical standard by those entities not providing these services is not authorized. 2015 (Resolution 21)* ACR–ASNR PRACTICE PARAMETER FOR BRAIN PET/CT IMAGING IN DEMENTIA PREAMBLE This document is an educational tool designed to assist practitioners in providing appropriate radiologic care for patients. Practice Parameters and Technical Standards are not inflexible rules or requirements of practice
Incident Atrial Fibrillation, Dementia and the Role of Anticoagulation: A Population-Based Cohort Study Atrial fibrillation (AF) is associated with dementia. Anticoagulation may modify this relationship, but it is unclear if this is due to stroke reduction alone. Age- and sex-matched individuals from the U.K. Clinical Practice Research Datalink (2008-2016) with and without an incident diagnosis of AF were followed for a new dementia diagnosis. We estimated adjusted hazard ratios (aHRs (...) ) for incident dementia diagnosis in the AF cohort, overall and stratified by anticoagulation status, using the matched non-AF cohorts as reference. We performed a sensitivity analysis excluding individuals with stroke/transient ischaemic attack (TIA) before the observation period. Over 193,082 person-years (mean follow-up 25.7 ± 0.1 months), 347/15,276 AF (2.3%) and 1,085/76,096 non-AF (1.4%) were newly diagnosed with dementia (aHR, 1.31, 95% confidence interval, 1.15-1.49). The AF group had more co
Effects of a modified mindfulness-based cognitive therapy for family caregivers of people with dementia: A pilot randomized controlled trial Caregivers of people with dementia experience high stress levels. Mindfulness-based cognitive therapy has been found to be effective in reducing stress and improving the psychological well-being of several populations.To explore the feasibility and preliminary effects of a modified mindfulness-based cognitive therapy for family caregivers of people (...) with dementia.In a single-blinded, parallel-group, randomized controlled trial, 36 caregivers of people with dementia were randomized to either the intervention group, receiving the 7-session modified mindfulness-based cognitive therapy in 10 weeks; or the control group, receiving the usual family care and brief education on dementia care. The brief education sessions were similar in frequency and duration to the intervention group. Various psychological outcomes of caregivers were assessed and compared
Scam Awareness Related to Incident Alzheimer Dementia and Mild Cognitive Impairment: A Prospective Cohort Study. Decreased scam awareness may be an early indicator of impending Alzheimer dementia and its precursor, mild cognitive impairment, but prior studies have not systematically examined the associations between scam awareness and adverse cognitive outcomes.To test the hypothesis that low scam awareness is associated with increased risk for incident Alzheimer dementia, mild cognitive (...) impairment, and Alzheimer disease pathology in the brain.Prospective cohort study of aging.Community-based study in the greater Chicago metropolitan area.935 older persons initially free of dementia.Scam awareness was measured via questionnaire, incident Alzheimer dementia and mild cognitive impairment were documented in detailed annual cognitive and clinical evaluations, and Alzheimer disease neuropathology was quantified after death among a subset of persons who died (n = 264). Proportional hazards
Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. Amyloid positron emission tomography (PET) detects amyloid plaques in the brain, a core neuropathological feature of Alzheimer disease.To determine if amyloid PET is associated with subsequent changes in the management of patients with mild cognitive impairment (MCI) or dementia of uncertain etiology.The Imaging Dementia (...) -Evidence for Amyloid Scanning (IDEAS) study was a single-group, multisite longitudinal study that assessed the association between amyloid PET and subsequent changes in clinical management for Medicare beneficiaries with MCI or dementia. Participants were required to meet published appropriate use criteria stating that etiology of cognitive impairment was unknown, Alzheimer disease was a diagnostic consideration, and knowledge of PET results was expected to change diagnosis and management. A total
Evidence Brief: Traumatic Brain Injury and Dementia Management Briefs eBrief-no150 -- Traumatic Brain Injury and Dementia Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no150 -- Traumatic Brain Injury and Dementia Health Services Research & Development Management eBrief no. 150 » Issue 150 March 2019 The report is a product of the VA/HSR&D Evidence Synthesis Program. Evidence (...) Brief: Traumatic Brain Injury and Dementia Traumatic brain injury (TBI) is a common condition among both civilian and military populations. While some TBIs cause acute symptoms that resolve over several weeks or months, evidence accumulated over nearly three decades suggests that TBI may lead to chronic neurodegenerative diseases such as dementia. More public awareness about TBI in active-duty service members as a risk factor for earlier onset of dementia and/or of Chronic Traumatic Encephalopathy
Association of Midlife Diet With Subsequent Risk for Dementia. Observational studies suggest that diet is linked to cognitive health. However, the duration of follow-up in many studies is not sufficient to take into account the long preclinical phase of dementia, and the evidence from interventional studies is not conclusive.To examine whether midlife diet is associated with subsequent risk for dementia.Population-based cohort study established in 1985-1988 that had dietary intake assessed (...) in 1991-1993, 1997-1999, and 2002-2004 and follow-up for incident dementia until March 31, 2017.Food frequency questionnaire to derive the Alternate Healthy Eating Index (AHEI), an 11-component diet quality score (score range, 0-110), with higher scores indicating a healthier diet.Incident dementia ascertained through linkage to electronic health records.Among 8225 participants without dementia in 1991-1993 (mean age, 50.2 years [SD, 6.1 years]; 5686 [69.1%] were men), a total of 344 cases of incident
Peri-operative care of people with dementia. Online Supporting Information Online Supporting Information S1 Sources of further information S2 Quality assessment/quality improvement (QA/QI) toolkit S4 Abbey pain scale  S1 Sources of further information • Alzheimer’s Society, Royal College of Nursing. This is me. A support tool to enable person-centred care. This proforma can be completed pre- operatively by a person with cognitive impairment or their carers, to provide information (...) for hospital staff about how to care for that person when they are admitted for surgery. https://www.alzheimers.org.uk/download/downloads/id/3423/this_is_me.pdf (accessed 20/02/2018). • Alzheimer’s Society. Fix Dementia Care: Hospitals. January, 2016. This document describes the experiences of people with dementia admitted to hospital, and recommends care improvements that should be made. https://www.alzheimers.org.uk/download/downloads/id/2907/fix_dementia_care_- _hospitals.pdf (accessed 20/02/2018
Traumatic Brain Injury and Dementia 4 February 2019 Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence Synthesis Program (ESP) Coordinating Center Portland VA Health Care System Portland, OR Mark Helfand, MD, MPH, MS, Director Evidence Brief: Traumatic Brain Injury and Dementia Authors: Kim Peterson, MS Stephanie Veazie, MPH Donald Bourne, MPH Johanna Anderson, MPH Evidence (...) Synthesis Program 4 Evidence Brief: TBI and Dementia Evidence Synthesis Program i PREFACE The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help: · Develop clinical policies informed by evidence; · Implement effective services to improve patient outcomes and to support VA clinical practice